Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; A new class of macrolide antibiotics, the azalides.
G. Michael Bright(Pfizer (United States)), Rachel J. Mason(Pfizer (United States)), Joseph DiBrino(Institute of Medicinal Plant Development), A. R. English(Pfizer (United States)), Lawrence A. Vincent(Institute of Medicinal Plant Development), C. R. Cimochowski(Pfizer (United States)), Frank Sciavolino(Institute of Medicinal Plant Development), J. A. Faiella(Pfizer (United States)), MARY MANOUSOS(Pfizer (United States)), JOLANTA NOWAKOWSKA(Institute of Medicinal Plant Development), LORI BRENNAN(Pfizer (United States)), MARGARET R. ANDERSON(Pfizer (United States)), James A. Retsema(Pfizer (United States)), ARTHUR E. GIRARD(Pfizer (United States)), R. M. Watrous(Institute of Medicinal Plant Development), D Girard(Pfizer (United States)), A. Nagel(Institute of Medicinal Plant Development), Kishor Desai(Institute of Medicinal Plant Development), ROBERTA J. BOROVOY(Pfizer (United States)), Carol P. Herbert(Pfizer (United States)), Jon Bordner(North Carolina State University)
Cited by 238
Related Papers
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
|Antimicrobial Agents and Chemotherapy|1987|461
CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization
|Antimicrobial Agents and Chemotherapy|1978|397
<b>Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, <i>mefA</i>, from <i>Streptococcus pyogenes</i></b>
|Molecular Microbiology|1996|360
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
|Antimicrobial Agents and Chemotherapy|1987|323
Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection
|Antimicrobial Agents and Chemotherapy|1996|154